This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (262)  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in JAMA  Topic Collections  • HIV/AIDS  • Alert me on articles by topic

Mark A. Wainberg, PhD; Gerald Friedland, MD

JAMA. 1998;279:1977-1983.

Widespread use of antiretroviral agents and increasing occurrence of human immunodeficiency virus (HIV) strains resistant to these drugs have given rise to a number of important issues. Some of these concerns are distinct from the obvious question of the relationship between drug resistance and treatment failure and have potentially widespread public health implications. The relevant issues include but are not limited to the following:(1) frequency with which drug-resistant virus may be transmitted via sexual, intravenous, or mother-to-child routes; (2) ability of drug-resistant variants to be transmitted, a question that relates, in part, to the relative fitness of such strains; (3) effectiveness of antiviral therapy in diminishing viral burden in both blood and genital secretions, and whether this may be compromised in persons harboring resistant virus; and (4) importance of patient adherence to antiviral therapy and its relationship to sustained reduction in viral load to minimize the appearance in and transmission of drug-resistant virus from both blood and genital secretions. Thus, prevention of both development of HIV drug resistance as well as transmission of drug-resistant variants is a central issue of public health importance. Unless this topic is appropriately addressed, the likelihood is that drug-resistant variants of HIV, if able to successfully replicate, will sustain the epidemic and limit the effectiveness of antiviral therapy.

From the McGill University AIDS Centre, Jewish General Hospital, Montreal, Quebec (Dr Wainberg), and the AIDS Program, Yale University School of Medicine, New Haven, Conn (Dr Friedland).

RELATED ARTICLES

Antiretroviral Drug Resistance Testing in Adults With HIV Infection: Implications for Clinical Management
Martin S. Hirsch, Brian Conway, Richard T. D'Aquila, Victoria A. Johnson, Françoise Brun-Vézinet, Bonaventura Clotet, Lisa M. Demeter, Scott M. Hammer, Donna M. Jacobsen, Daniel R. Kuritzkes, Clive Loveday, John W. Mellors, Stefano Vella, Douglas D. Richman, and for the International AIDS Society–USA Panel
JAMA. 1998;279(24):1984-1991.
ABSTRACT | FULL TEXT  

Drug-Resistant HIV-1: The Virus Strikes Back
Douglas L. Mayers
JAMA. 1998;279(24):2000-2002.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Effect of a clinical pharmacist's interventions on duration of antiretroviral-related errors in hospitalized patients
Heelon et al.
Am J Health Syst Pharm 2007;64:2064-2068.
ABSTRACT | FULL TEXT  

Bridging the Gap Between Antiretroviral Access and Adherence in Mexico
Campero et al.
Qual Health Res 2007;17:599-611.
ABSTRACT  

Frequency of and risk factors for HIV dementia in an HIV clinic in sub-Saharan Africa
Wong et al.
Neurology 2007;68:350-355.
ABSTRACT | FULL TEXT  

Psychosocial Factors Predict CD4 and Viral Load Change in Men and Women With Human Immunodeficiency Virus in the Era of Highly Active Antiretroviral Treatment
Ironson et al.
Psychosom. Med. 2005;67:1013-1021.
ABSTRACT | FULL TEXT  

Atazanavir Signature I50L Resistance Substitution Accounts for Unique Phenotype of Increased Susceptibility to Other Protease Inhibitors in a Variety of Human Immunodeficiency Virus Type 1 Genetic Backbones
Weinheimer et al.
Antimicrob. Agents Chemother. 2005;49:3816-3824.
ABSTRACT | FULL TEXT  

The Social Realities of Adherence to Protease Inhibitor Regimens: Substance Use, Health Care and Psychological States
Halkitis et al.
J Health Psychol 2005;10:545-558.
ABSTRACT  

The Challenge of HIV for Feminist Theory
Rosengarten
Feminist Theory 2004;5:205-222.
ABSTRACT  

Highly Active Antiretroviral Therapy and Sexual Risk Behavior: A Meta-analytic Review
Crepaz et al.
JAMA 2004;292:224-236.
ABSTRACT | FULL TEXT  

Paradoxes of adherence and drug resistance to HIV antiretroviral therapy
Bangsberg et al.
J Antimicrob Chemother 2004;53:696-699.
ABSTRACT | FULL TEXT  

Jewish Religious Ethics Mandate Access to Antiretroviral Drugs in Developing Countries
Spira and Wainberg
J Int Assoc Physicians AIDS Care (Chic Ill) 2004;3:7-11.
ABSTRACT  

Novel bis-Tetrahydrofuranylurethane-Containing Nonpeptidic Protease Inhibitor (PI) UIC-94017 (TMC114) with Potent Activity against Multi-PI-Resistant Human Immunodeficiency Virus In Vitro
Koh et al.
Antimicrob. Agents Chemother. 2003;47:3123-3129.
ABSTRACT | FULL TEXT  

Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance
Spira et al.
J Antimicrob Chemother 2003;51:229-240.
ABSTRACT | FULL TEXT  

Medication adherence among HIV+ adults: Effects of cognitive dysfunction and regimen complexity
Hinkin et al.
Neurology 2002;59:1944-1950.
ABSTRACT | FULL TEXT  

Reversion of the M184V Mutation in Simian Immunodeficiency Virus Reverse Transcriptase Is Selected by Tenofovir, Even in the Presence of Lamivudine
Murry et al.
J. Virol. 2002;77:1120-1130.
ABSTRACT | FULL TEXT  

Hair It Is: The Long and Short of Monitoring Antiretroviral Treatment
Gandhi and Greenblatt
ANN INTERN MED 2002;137:696-697.
FULL TEXT  

Highly active antiretroviral treatment does not increase sexual risk behaviour among French HIV infected injecting drug users
Bouhnik et al.
J. Epidemiol. Community Health 2002;56:349-353.
ABSTRACT | FULL TEXT  

Rapid and Sensitive Oligonucleotide Ligation Assay for Detection of Mutations in Human Immunodeficiency Virus Type 1 Associated with High-Level Resistance to Protease Inhibitors
Beck et al.
J. Clin. Microbiol. 2002;40:1413-1419.
ABSTRACT | FULL TEXT  

Persistence and Fitness of Multidrug-Resistant Human Immunodeficiency Virus Type 1 Acquired in Primary Infection
Brenner et al.
J. Virol. 2002;76:1753-1761.
ABSTRACT | FULL TEXT  

A Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor, UIC-94003 (TMC-126), and Selection of a Novel (A28S) Mutation in the Protease Active Site
Yoshimura et al.
J. Virol. 2002;76:1349-1358.
ABSTRACT | FULL TEXT  

Evaluation of Adherence to Highly Active Antiretroviral Therapy
Martin-Fernandez et al.
Arch Intern Med 2001;161:2739-2740.
FULL TEXT  

4'-Ethynyl Nucleoside Analogs: Potent Inhibitors of Multidrug-Resistant Human Immunodeficiency Virus Variants In Vitro
Kodama et al.
Antimicrob. Agents Chemother. 2001;45:1539-1546.
ABSTRACT | FULL TEXT  

Gay Men and HIV/AIDS Risk Management
Flowers
Health (London) 2001;5:50-75.
ABSTRACT  

Management of HIV-1 Infection in Adults and Adolescents
Eugenio and Zeind
Journal of Pharmacy Practice 2000;13:426-441.
ABSTRACT  

Protease Inhibitors: Changing the Way AIDS Case Management Does Business
Merithew and Davis-Satterla
Qual Health Res 2000;10:632-645.
ABSTRACT  

Production of resistant HIV mutants during antiretroviral therapy
Ribeiro and Bonhoeffer
Proc. Natl. Acad. Sci. USA 2000;97:7681-7686.
ABSTRACT | FULL TEXT  

Adherence to Protease Inhibitor Therapy and Outcomes in Patients with HIV Infection
Paterson et al.
ANN INTERN MED 2000;133:21-30.
ABSTRACT | FULL TEXT  

The Language of Medication-Taking
Steiner and Earnest
ANN INTERN MED 2000;132:926-930.
FULL TEXT  

Use of Drug Effect Interaction Modeling with Monte Carlo Simulation To Examine the Impact of Dosing Interval on the Projected Antiviral Activity of the Combination of Abacavir and Amprenavir
Drusano et al.
Antimicrob. Agents Chemother. 2000;44:1655-1659.
ABSTRACT | FULL TEXT  

Antiviral agent based on the non-structural protein targeting the maturation process of HIV-1: expression and susceptibility of chimeric Vpr as a substrate for cleavage by HIV-1 protease
Serio et al.
Protein Eng Des Sel 2000;13:431-436.
ABSTRACT | FULL TEXT  

Selection and Characterization of Human Immunodeficiency Virus Type 1 Variants Resistant to the (+) and (-) Enantiomers of 2'-Deoxy-3'-Oxa-4'-Thio-5-Fluorocytidine
Richard et al.
Antimicrob. Agents Chemother. 2000;44:1127-1131.
ABSTRACT | FULL TEXT  

Therapeutic dilemma: The use of anticonvulsants in HIV-positive individuals
Romanelli et al.
Neurology 2000;54:1404-1407.
ABSTRACT | FULL TEXT  

Drug Resistance Patterns, Genetic Subtypes, Clinical Features, and Risk Factors in Military Personnel with HIV-1 Seroconversion
Brodine et al.
ANN INTERN MED 1999;131:502-506.
ABSTRACT | FULL TEXT  

HIV-1 Drug Resistance in Newly Infected Individuals
Boden et al.
JAMA 1999;282:1135-1141.
ABSTRACT | FULL TEXT  

Primary HIV-1 Resistance: A New Phase in the Epidemic?
Pomerantz
JAMA 1999;282:1177-1179.
FULL TEXT  

Reconstitution of Human Thymic Implants Is Limited by Human Immunodeficiency Virus Breakthrough during Antiretroviral Therapy
Amado et al.
J. Virol. 1999;73:6361-6369.
ABSTRACT | FULL TEXT  

Use of Antiretroviral Therapy by Intravenous Drug Users With HIV
Anderson et al.
JAMA 1999;281:699-701.
FULL TEXT  

Improving Patient Compliance With HIV Treatment Regimens
Ungvarski et al.
JAMA 1998;280:1745-1745.
FULL TEXT  

Drug-Resistant HIV-1: The Virus Strikes Back
Mayers
JAMA 1998;279:2000-2002.
FULL TEXT